Page 4 - Dr Reddy's
Stocks to Watch: RIL, HUL, Dr.Reddy's, PNB Housing, Future Retail, Banks
Reliance Industries is likely to be in limelight as the company is looking to take advantage of the surging diesel demand in Europe in the backdrop of Russia-Ukraine conflict.
 "Stocks to Watch: RIL, HUL, Dr.Reddy's, PNB Housing, Future Retail, Banks")
Sell-off toll! HDFC twins, HUL, Dr.Reddy's among Nifty50 stks at 52-wk lows
Apart from the 8 stocks among the Nifty50 index, a total of 26 stocks too dropped to their respective 52-week lows among the Nifty500 index.
 "Sell-off toll! HDFC twins, HUL, Dr.Reddy's among Nifty50 stks at 52-wk lows")
Russia-Ukraine crisis: Indian pharma exporters in wait and watch mode
An official of Dr Reddy's Laboratories said they are closely monitoring the developments and ensuring the well-being of their staff in that region is the first and foremost priority
 "Russia-Ukraine crisis: Indian pharma exporters in wait and watch mode")
Binnopharm to acquire 2 anti-bacterial brands from Dr Reddy's
During the transition period, Dr Reddy's will continue to supply the product to Binnopharm Group to ensure availability in the market
 "Binnopharm to acquire 2 anti-bacterial brands from Dr Reddy's")
Stocks to Watch: DRL, Mankind, Sun Pharma, Wipro, Kalpataru, TTML, Airlines
Ambuja Cement, Nestle India and Veritas to announce December quarter results today.
Dr Reddy's to launch Molflu at Rs 35 per capsule for Covid treatment
The overall cost for a patient treated with a 5-day course of 40 capsules of the generic drug, to be sold under brand name 'Molflu', will come up to Rs 1,400
 "Dr Reddy's to launch Molflu at Rs 35 per capsule for Covid treatment")
Dr Reddy's inks pact with Citius Pharma to sell rights to anti-cancer agent
The drug firm said it has entered into a definitive agreement with Citius to sell all of its rights to E7777 and certain related assets.
 "Dr Reddy's inks pact with Citius Pharma to sell rights to anti-cancer agent")
Dr Reddy's, Natco Pharma launch generic cancer drug in Canada
Dr Reddy's Laboratories and Natco Pharma on Thursday said they have launched generic capsules used in the treatment of multiple myeloma and myelodysplastic syndrome patients in the Canadian market.
 "Dr Reddy's, Natco Pharma launch generic cancer drug in Canada")
DRL seeks a booster from Sputnik V but hurdles in scaling up remain
Even as the company investigates complaints of malpractice in the Ukraine, hurdles in scaling up the Russian vaccine remain the bigger challenge in the near term
 "DRL seeks a booster from Sputnik V but hurdles in scaling up remain")
Dr Reddy's to sell US, Canada territory rights for migraine drug to BDSI
Drug firm Dr Reddy's Laboratories on Wednesday said it has entered into a definitive agreement with BioDelivery Sciences International, Inc., to sell its US and Canada territory rights
 "Dr Reddy's to sell US, Canada territory rights for migraine drug to BDSI")
DRL stock falls 10% after missing Q1 estimates, probe by US SEC
The stock fell 10.4 per cent to Rs 4,844.35 (hitting the lower circuit) on Tuesday after reporting lower-than-expected quarterly earnings for Q1FY22
Covid-19 pandemic: Sputnik V vaccine imports likely to improve from August
Trials on adolescents in Russia expected to end by October: DRL
 "Covid-19 pandemic: Sputnik V vaccine imports likely to improve from August")
Indian pharma industry to touch $130 bn by 2030: Dr Reddy's chairman
The Indian pharmaceutical industry is expected to grow almost by three times to about 130 billion US dollars by 2030
Sputnik V second dose shortage to delay India's full rollout: Dr Reddy's
Dr. Reddy's had received about 3 million first doses by June 1 and about 360,000 doses of the second by early this month, the company and the Indian government have said
 "Sputnik V second dose shortage to delay India's full rollout: Dr Reddy's")
Shilpa Medicare arm inks pact with Dr Reddy's to manufacture Sputnik V vax
Drug firm Shilpa Medicare on Monday said its arm has entered into a definitive agreement with Dr Reddy's Laboratories for manufacturing of Russian COVID-19 vaccine Sputnik V. "The company, via its wholly owned subsidiary Shilpa Biologicals Pvt Ltd (SBPL), has entered into a three year definitive agreement with Dr Reddy's Laboratories for production-supply of the Sputnik V vaccine from its integrated biologics R&D cum manufacturing center at Dharwad, Karnataka," Shilpa Medicare said in a regulatory filing. The targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses (50 million of component 1 and 50 million of component 2), from the date of start of commercial production, the company added. Shilpa Medicare said Dr Reddy's will facilitate the transfer of the sputnik technology to SBPL. Under the agreement, SBPL will be responsible for manufacture of the vaccine, while Dr Reddy's is responsible for distribution/marketing of the vaccine in its ...
Dr Reddy's to get 36 mn doses of Sputnik V vaccine in next few months
The drugmaker on Friday reported a 27.6% drop in fourth-quarter consolidated net profit, compared with a year earlier.
 "Dr Reddy's to get 36 mn doses of Sputnik V vaccine in next few months")
Dr Reddy's receives DCGI approval for restricted emergency use of Sputnik V
Drug major Dr Reddy's Laboratories on Tuesday said it has received approval from Indian drug regulator for restricted emergency use of Covid-19 vaccine Sputnik V in the country
India approves Sputnik V vaccine, to produce 850 mn doses annually: RDIF
The RDIF has said that India has become the 60th country to approve the use of Sputnik V against coronavirus
 "India approves Sputnik V vaccine, to produce 850 mn doses annually: RDIF")
Dr Reddy's to submit more data on Covid-19 vaccine Sputnik V by July
Colour-coded doses will have two different antigens
Dr Reddy s eyes to launch Sputnik V vaccine for Covid-19 under EUA in March
Dr Reddys Laboratories (DRL) on Friday said it expected Russia's COVID-19 vaccine Sputnik V to be launched in India through Emergency Use Authorisation (EUA) by March this year.